0000000000234096

AUTHOR

Alberto Albanese

showing 5 related works from this author

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

2015

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were e…

AdultMale0301 basic medicineamyotrophic lateral sclerosismedicine.medical_specialtyALS - TUDCA - clinical trialmedicine.drug_classPilot ProjectsAmyotrophic lateral sclerosis; Cholic acids; Tauroursodeoxycholic acid; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Drug Therapy Combination; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Riluzole; Taurochenodeoxycholic Acid; Outcome Assessment (Health Care); Neurology; Neurology (clinical)PlaceboNeuroprotectionGastroenterologyTaurochenodeoxycholic AcidOutcome Assessment (Health Care)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodDrug TherapyInternal medicinemedicineCholic acidHumansAmyotrophic lateral sclerosisAdverse effectAmyotrophic lateral sclerosiAgedtauroursodeoxycholic acidRiluzoleBile acidbusiness.industryTauroursodeoxycholic acidMiddle Agedmedicine.diseaseRiluzoleSurgerySettore MED/26 - NEUROLOGIANeuroprotective Agentscholic acids030104 developmental biologyNeurologychemistryTolerabilityCombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean Journal of Neurology
researchProduct

Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.

2010

408 Positional cerebral ischemia (PCI) is an extremely rare condition in which dramatic central nervous system deficits are triggered by standing in patients with severe stenosis or occlusion of the major brain-supplying blood vessels [1] . Because PCI is generally associated with orthostatic hypotension [2, 3] , a hemodynamic mechanism has been proposed [4] . However, PCI has been reported even in patients without orthostatic hypotension [1] . The treatment is medical, but surgery can be considered in refractory cases (endarterectomy for carotid artery stenosis or either highor low-flow extra-intracranial bypass – for carotid occlusion) [3] . We report a case of PCI associated with middle …

Malemedicine.medical_specialtyMiddle Cerebral ArterySettore MED/09 - Medicina InternaTiclopidinePostureIschemiaHemodynamicsOrthostatic vital signsmedicine.arteryInternal medicineParietal LobeOcclusionmedicineHumansThrombophiliacardiovascular diseasesCerebral perfusion pressureTomography Emission-Computed Single-Photonpositional ischemia Extracranial by-passAspirinCerebral Revascularizationbusiness.industryInfarction Middle Cerebral ArteryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingClopidogrelTemporal ArteriesParesisHemiparesisBlood pressureNeurologyIschemic Attack TransientAnesthesiaMiddle cerebral arteryCardiologyNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCerebrovascular diseases (Basel, Switzerland)
researchProduct

Reply to Dr Michaudet al.

2015

There is no abstract

Cholagogues and Cholereticsbusiness.industryEndoplasmic reticulumAmyotrophic Lateral SclerosisTaurochenodeoxycholic acidTauroursodeoxycholic acidMitochondrionPharmacologyEndoplasmic Reticulummedicine.diseaseTaurochenodeoxycholic Acidchemistry.chemical_compoundNeurologychemistryImmunologyUnfolded Protein ResponsemedicineUnfolded protein responseAnimalsHumansTUDCA ALSSettore MED/26 - NeurologiaNeurology (clinical)Amyotrophic lateral sclerosisbusinessEuropean Journal of Neurology
researchProduct

Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study

2020

Background\ud Functional motor disorders (FMDs) are abnormal movements that are significantly altered by distractive maneuvers and are incongruent with movement disorders seen in typical neurological diseases.\ud \ud Objective\ud The objectives of this article are to (1) describe the clinical manifestations of FMDs, including nonmotor symptoms and occurrence of other functional neurological disorders (FND); and (2) to report the frequency of isolated and combined FMDs and their relationship with demographic and clinical variables.\ud \ud Methods\ud For this multicenter, observational study, we enrolled consecutive outpatients with a definite diagnosis of FMDs attending 25 tertiary movement …

0301 basic medicineWeaknessPediatricsmedicine.medical_specialtyMovement disordersfunctional neurological disordersdiagnosisPopulationfunctional weakneDisease030105 genetics & heredityfunctional weakness03 medical and health sciences0302 clinical medicinefunctional neurological disordermedicineeducationResearch Articleseducation.field_of_studyfunctional neurological disorders; functional dystonia; functional tremor; functional weakness; diagnosisbusiness.industryfunctional neurological disorders functional dystonia functional tremor functional weakness diagnosisFunctional weaknessfunctional dystoniatremorNeurologyMulticenter studyAnxietyfunctional tremorSettore MED/26 - NeurologiaObservational studydystoniaNeurology (clinical)medicine.symptombusinessfunctional neurological disorders functional dystonia functional tremor functional weakness diagnosis.030217 neurology & neurosurgery
researchProduct

Early DEtection of wEaring off in Parkinson disease: The DEEP study

2014

Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on lev…

QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drug
researchProduct